ReviewFrontiers in psychiatry2025
Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder.
Review in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic-assisted therapy is a remarkably promising treatment for substance use disorders and for alcohol use disorder (AUD) in particular. Research supporting psychedelics as a safe and effective pharmacotherapy for AUD and its comorbid psychiatric conditions dates from the late1940s and includes over 2,000 published studies. There are, however, challenges to the clinical implementation of psychedelics on a scale appropriate to a highly prevalent disease. Virtual reality applications can aid in meeting these challenges. Studies have shown that virtual reality simulations of psychedelic phenomenology (VRP) can replicate neurophysiological and behavioral markers of classic serotonergic psychedelics when viewed by healthy subjects. The results of these studies suggest VRP may have utility as an adjunct to or replacement for aspects of psychedelic-assisted therapy. Here, we introduce four potential clinical applications for VRP in psychedelic-assisted therapy: to prepare for psychedelics, to extend and enhance their efficacy, to facilitate integration following psychedelic dosing, and to standardize the set and setting. VRP may also have application to clinical research in psychedelics as a placebo and as a tool for interrogating the subjective experience of psychedelics in the therapeutic setting. Integrating virtual reality into psychedelic therapy and research holds the promise of new possibilities for psychedelic treatment and new pathways to their implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.